Exact Sciences falls on CellMax cancer diagnostic data

Exact Sciences Corp. (NASDAQ:EXAS) was off $5.27 (10%) to $47.68 on Wednesday after CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected

Read the full 274 word article

User Sign In